Valerio Therapeutics : 2025 Half-Yearly Financial Report

About this update from Valerio Therapeutics

Société anonyme au capital de 4.888.478,61 euros Siège social : 49, boulevard du général Martial Valin - 75015 Paris 410 910 095 R.C.S. Paris 2025 HALF-YEAR FINANCIAL REPORT SOMMAIRE PREAMBLE 4 SCOPE OF THE GROUP 5 BUSINESS DEVELOPMENTS AND SIGNIFICANT EVENTS DURING THE FIRST HALF OF THE FISCAL YEAR 5 Research and development 5 Financing 6 Governance 6 Key corporate communications during the first half of 2025 7 IMPACT ON THE FINANCIAL POSITION AND RESULTS 8 Review of accounts and results 8 Cash position 9 MAIN RISKS AND UNCERTAINTIES FOR THE NEXT SEMESTER 9 Financial risks 9 Business risks 10 Legal and regulatory risks 10 Insurance and risk coverage 11 5.4. Litigation 11 EXPECTED DEVELOPMENT OF THE GROUP'S SITUATION AND OUTLOOK . 11 Main future investments and financing strategy 12 Significant Events Since the End of the Period 12 RELATED PARTY TRANSACTIONS 14 CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2025 14 Consolidated Statement of Financial Position 15 Consolidated Statement of Comprehensive Income 16 Consolidated Statement of Changes in Equity 17 Consolidated Statement of Cash Flows 18 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS 19 NOTE 1: BASIS OF PREPARATION OF THE FINANCIAL STATEMENTS 19 NOTE 2: CONSOLIDATION SCOPE 19 NOTE 3 : REPORTING ON OPERATING SEGMENTS (IFRS 8) 20 NOTE 4 : INTANGIBLE ASSETS 20 NOTE 5 : RIGHT-OF-USE ASSETS 20 NOTE 6 : CURRENT ASSETS 21 NOTE 7 : CASH AND CASH EQUIVALENTS 21 NOTE 8 : SHAREHOLDERS' EQUITY 22 NOTE 9 : NON-CURRENT LIABILITIES 25 NOTE 10 : CURRENT LIABILITIES 26 NOTE 11 : OPERATING INCOME AND EXPENSES 27 NOTE 12 : FINANCIAL RESULT 28 NOTE 13 : EARNINGS PER SHARE 28 NOTE 14 : RELATED PARTIES 29 NOTE 15 : SUBSEQUENT EVENTS 29 CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE INTERIM FINANCIAL REPORT 30 ‌PREAMBLE Valerio Therapeutics (formerly Onxeo) (the "Company") is a biotechnology company developing innovative drug candidates through its two proprietary platforms: the V-body platform, which generates single-domain therapeutic antibodies, and the integrated chemistry platform, designed to develop immunoconjugates. The Company aims to advance novel or breakthrough compounds from early translational research to clinical proof of concept - a key value inflection point that is highly attractive to potential partners. Valerio Therapeutics is listed on the Euronext Growth market in Paris. The C...

View stock analysis, news, and events for Valerio Therapeutics